Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 9:11:59-73.
doi: 10.2147/PTT.S288345. eCollection 2021.

Updates on the Treatment of Erythrodermic Psoriasis

Yang Lo  1 , Tsen-Fang Tsai  2
Affiliations
Review

Updates on the Treatment of Erythrodermic Psoriasis

Yang Lo et al. Psoriasis (Auckl). .

Abstract

Erythrodermic psoriasis (EP) is a rare variant of psoriasis, which is potentially life threatening and often resistant to conventional therapy. Biologics have revolutionized the treatment of plaque-type psoriasis, and shown promise in EP. However, due to the lack of head-to-head studies and the rarity of EP, no high level evidence-based treatment guidelines for EP have been established, and the evidence of treatment of EP is limited to case reports or small case series. Here, we present a narrative review focusing on the up-to-date information for the treatment of EP.

Keywords: erythrodermic psoriasis; treatment.

PubMed Disclaimer

Conflict of interest statement

Dr Tsen‐Fang Tsai has conducted clinical trials and/or received honoraria for serving as a consultant for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, EliLilly, Galderma, GSK‐Stiefel, Janssen‐Cilag, Leo‐Pharma, Merck Sharp & Dohme, Novartis, Pfizer and Serono International SA (now Merck Serono International). Dr Yang Lo has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Treatment algorithm of EP, suggested by the author.
See this image and copyright information in PMC

References

    1. Rosenbach M, Hsu S, Korman NJ, et al. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;62(4):655–662. doi:10.1016/j.jaad.2009.05.048 - DOI - PubMed
    1. Boyd AS, Menter A. Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients. J Am Acad Dermatol. 1989;21(5 Pt 1):985–991. doi:10.1016/S0190-9622(89)70287-5 - DOI - PubMed
    1. Yan D, Afifi L, Jeon C, Cordoro KM, Liao W. A cross-sectional study of the distribution of psoriasis subtypes in different ethno-racial groups. Dermatol Online J. 2018;24(7):13030/qt5z21q4k2. - PubMed
    1. Chen HS, Tseng MP, Tsai TF. An epidemiologic study of Taiwanese psoriatic patients in a single clinic. Dermatol Sinica. 2003;21(3):216–224.
    1. Stinco G, Errichetti E. Erythrodermic psoriasis: current and future role of biologicals. BioDrugs. 2015;29(2):91–101. doi:10.1007/s40259-015-0119-4 - DOI - PubMed